GO
Loading...

Biogen Inc

More

  • Final Glance: Biotechnology companies Monday, 27 Apr 2015 | 6:06 PM ET

    Amgen Inc. fell $5.53 or 3.3 percent, to $162.38. Biogen Idec fell $12.44 or 3.1 percent, to $389.27. Celgene Corp. fell $4.00 or 3.4 percent, to $114.72.

  • Midday Glance: Biotechnology companies Monday, 27 Apr 2015 | 1:50 PM ET

    Amgen Inc. fell $5.07 or 3.0 percent, to $162.84. Biogen Idec fell $11.37 or 2.8 percent, to $390.34. Celgene Corp. fell $3.51 or 3.0 percent, to $115.20.

  • Early Glance: Biotechnology companies Monday, 27 Apr 2015 | 11:25 AM ET

    Amgen Inc. fell $1.08 or. 6 percent, to $166.83. Biogen Idec fell $1.10 or. 3 percent, to $400.62. Celgene Corp. fell$. 50 or. 4 percent, to $118.21.

  • Final Glance: Biotechnology companies Friday, 24 Apr 2015 | 8:08 PM ET

    Amgen Inc. fell $1.26 or. 7 percent, to $167.91. Biogen Idec fell $28.57 or 6.6 percent, to $401.71. Celgene Corp. rose $2.62 or 2.3 percent, to $118.71.

  • Xerox and Amazon are big market movers Friday, 24 Apr 2015 | 4:34 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:. Xerox Corp., down $1.15 to $11.99. Rival Comcast dropped its $45 billion buyout bid for the cable company after pushback from the Federal Communications Commission.

  • Midday Glance: Biotechnology companies Friday, 24 Apr 2015 | 1:36 PM ET

    Amgen Inc. fell $1.01 or. 6 percent, to $168.16. Biogen Idec fell $25.40 or 5.9 percent, to $404.88. Celgene Corp. rose $3.05 or 2.6 percent, to $119.14.

  • April 24- Slowing sales of Biogen Inc's key oral multiple sclerosis drug Tecfidera and a delay in a data readout for its keenly watched Alzheimer's drug sent the company's stock down as much as 8 percent on Friday. If Tecfidera's U.S. trajectory does not improve, Biogen's revenue growth may come in at the lower end of its previously issued forecast, Chief...

  • Early Glance: Biotechnology companies Friday, 24 Apr 2015 | 10:55 AM ET

    Amgen Inc. fell $1.09 or. 6 percent, to $168.08. Biogen Idec fell $26.23 or 6.1 percent, to $404.05. Celgene Corp. rose$. 79 or. 7 percent, to $116.88.

  • April 24- Sales of Biogen Inc's key oral multiple sclerosis drug Tecfidera fell on a sequential basis in the first quarter for the first time since its launch in 2013, sending the company's stock down as much as 8 percent on Friday. If Tecfidera's U.S. trajectory does not improve, Biogen's revenue growth may come in at the lower end of its previously issued...

  • Early movers: BIIB, XRX, MSFT, AMZN, SBUX & more Friday, 24 Apr 2015 | 8:09 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Tecfidera raked in sales of $824.9 million in the first quarter ended March 31, compared with $506 million a year earlier, but missed consensus projections of about $931 million, according to Deutsche Bank. We saw moderating patient growth of Tecfidera in the United States and Germany, Chief Executive George Scangos said in a statement. Net income attributable...

  • Biogen results rise, but miss 1Q forecasts Friday, 24 Apr 2015 | 7:21 AM ET

    But that missed Wall Street expectations, with the average estimate of 18 analysts surveyed by Zacks Investment Research expecting $3.92 per share. Nineteen analysts surveyed by Zacks expected $2.66 billion. The disappointing results sent Biogen Idec shares down $19.53, or 4.5 percent, to $410.75 in premarket trading shortly before the market open.

  • April 24- Biogen Inc reported a 71 percent rise in quarterly profit, driven by strong demand for its top-selling oral multiple sclerosis drug, Tecfidera. The U.S. biotechnology company's net profit soared to $822.5 million, or $3.49 per share, in the first quarter ended March 31, from $480 million, or $2.02 per share, a year earlier. Excluding items, Biogen earned...

  • Wall Street looks to finish week strong Friday, 24 Apr 2015 | 6:10 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Big tech names will dominate market movements on Friday, with continuation of Greece debt talks and just one economic data point expected.

  • Traders focus on tech, but keep one eye on Greece Thursday, 23 Apr 2015 | 6:42 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Big tech names will dominate market movements on Friday, with continuation of Greece debt talks and just one economic data point expected.

  • Final Glance: Biotechnology companies Thursday, 23 Apr 2015 | 6:05 PM ET

    Amgen Inc. rose$. 07 or percent, to $169.17. Biogen Idec rose $6.71 or 1.6 percent, to $430.28. Celgene Corp. rose$. 55 or. 5 percent, to $116.09.

  • Four trades to go before the closing bell Thursday, 23 Apr 2015 | 2:53 PM ET

    The "Halftime Report" traders give their top trades for the second half of the trading day.

  • Midday Glance: Biotechnology companies Thursday, 23 Apr 2015 | 1:24 PM ET

    Amgen Inc. fell$. 81 or. 5 percent, to $168.29. Biogen Idec rose $5.95 or 1.4 percent, to $429.52. Celgene Corp. rose$. 39 or. 3 percent, to $115.93.

  • Early Glance: Biotechnology companies Thursday, 23 Apr 2015 | 11:02 AM ET

    Amgen Inc. fell $1.85 or 1.1 percent, to $167.25. Biogen Idec fell $1.23 or. 3 percent, to $422.34. Celgene Corp. fell$. 19 or. 2 percent, to $115.35.

  • Bang for your buck: Where earnings surprises are Thursday, 23 Apr 2015 | 8:28 AM ET
    Traders on the floor of the New York Stock Exchange.

    Three sectors are seeing the biggest rallies following earnings reports. Where investors should place future bets.